Generics

Five things for pharma marketers to know: Tuesday, January 23, 2018

Five things for pharma marketers to know: Tuesday, January 23, 2018

By

FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW

Five things for pharma marketers to know: Friday, January 19, 2018

Five things for pharma marketers to know: Friday, January 19, 2018

By

Biogen, UCB reportedly showing interest in Acorda acquisition; Kite Pharma and Pfizer to develop combo lymphoma therapy; hospitals to form generics nonprofit

Five things for pharma marketers to know: Tuesday, January 9, 2018

Five things for pharma marketers to know: Tuesday, January 9, 2018

By

Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018

Five things for pharma marketers to know: Thursday, January 4, 2018

Five things for pharma marketers to know: Thursday, January 4, 2018

By

Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy

Five things for pharma marketers to know: Tuesday, December 26, 2017

Five things for pharma marketers to know: Tuesday, December 26, 2017

By

Roche to buy Ignyta for $1.7 billion; FDA OKs Valeant eye drop for OTC sale; Kmart settles prescription drug fraud allegations

Five things for pharma marketers to know: Thursday, December 14, 2017

Five things for pharma marketers to know: Thursday, December 14, 2017

By

Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business

Five things for pharma marketers to know: Friday, December 15, 2017

Five things for pharma marketers to know: Friday, December 15, 2017

By

FDA approves first topical skin growth treatment; Teva to cut 14,000 jobs; Novartis Oncology CEO resigns

Five things for pharma marketers to know: Wednesday, December 13, 2017

Five things for pharma marketers to know: Wednesday, December 13, 2017

By

Teva diminishes debt with job cuts and sale; FDA to study whether consumers can detect misleading ads; AbbVie, Roche present positive Phase-III data at ASH

Five things for pharma marketers to know: Monday, December 11, 2017

Five things for pharma marketers to know: Monday, December 11, 2017

By

Pfizer's Viagra generic to sell for half the price; GSK seeks oncology deals; Ionis' experimental Huntington's drug tackles toxic protein for the first time

Five things for pharma marketers to know: Monday, November 27, 2017

Five things for pharma marketers to know: Monday, November 27, 2017

By

Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up

Five things for pharma marketers to know: Thursday, November 2, 2017

Five things for pharma marketers to know: Thursday, November 2, 2017

By

Teva reports lower-than-expected Q3 earnings; BI and Dicerna partner in NASH drug development; AstraZeneca's experimental asthma drug fails in Phase-III

Five things for pharma marketers to know: Wednesday, August 9, 2017

Five things for pharma marketers to know: Wednesday, August 9, 2017

By

The FDA on pace for record generic drug approvals; CVS Health CEO doubts Amazon's entrance to pharmacy market; Sanofi to develop cancer immunotherapy

Five things for pharma marketers to know: Thursday, July 27, 2017

Five things for pharma marketers to know: Thursday, July 27, 2017

By

Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug

Five things for pharma marketers to know: Monday, July 24, 2017

Five things for pharma marketers to know: Monday, July 24, 2017

By

Samsung Bioepis launches Remicade biosimilar; WHO encourages uses of generic version of Sovaldi; nearly 20 million people with HIV on treatment

Five things for pharma marketers to know: Thursday, June 29, 2017

Five things for pharma marketers to know: Thursday, June 29, 2017

By

Walgreens ends merger with Rite Aid; Biogen hires former Novartis exec as SVP of corporate affairs; FDA takes new measures to drive drug pricing competition

Five things for pharma marketers to know: Thursday, June 22, 2017

Five things for pharma marketers to know: Thursday, June 22, 2017

By

The FDA plans public meeting to encourage generic competition; Mylan reportedly offered rebates to six Medicaid programs; Republicans to present draft bill for Obamacare replacement

Five things for pharma marketers to know: Thursday, June 15, 2017

Five things for pharma marketers to know: Thursday, June 15, 2017

By

Google invests in European biotechs; hospitals that restrict sales-rep visits more likely to prescribe cheaper generics; AI could help doctors with new research

Five things for pharma marketers to know: Monday, June 12, 2017

Five things for pharma marketers to know: Monday, June 12, 2017

By

Teva gets FDA approval for Truvada generic; the FDA rejects Coherus' Neulasta biosimilar; only 17% of Americans find health industries to be innovative

Five things for pharma marketers to know: Friday, June 9, 2017

Five things for pharma marketers to know: Friday, June 9, 2017

By

The FDA asks Endo to take opioid off the market; Lilly partners with Swiss biotech; House committee advances PDUFA bill — without off-label provision

Five things for pharma marketers to know: Friday, April 28, 2017

Five things for pharma marketers to know: Friday, April 28, 2017

By

Express Scripts-Anthem deal highlights profitability for PBMs; Sarepta CEO steps down; study says NHS cancer drug fund was ineffective

Five things for pharma marketers to know: Wednesday, February 15, 2017

Five things for pharma marketers to know: Wednesday, February 15, 2017

By

Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto

GSK prepares for Advair competition

GSK prepares for Advair competition

By

If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.

Five things for pharma marketers to know: Tuesday, February 7, 2017

Five things for pharma marketers to know: Tuesday, February 7, 2017

By

Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer

Five things for pharma marketers to know: Wednesday, January 18, 2017

Five things for pharma marketers to know: Wednesday, January 18, 2017

By

Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz's Xyrem

Five things for pharma marketers to know: Tuesday, February 2, 2016

Five things for pharma marketers to know: Tuesday, February 2, 2016

By

Gleevec generics hit shelves; four OxyContin patents are invalidated; Sanofi axes 600 positions

Five things for pharma marketers to know: Thursday, September 3, 2015

Five things for pharma marketers to know: Thursday, September 3, 2015

By

Novartis launches Zarxio, the first US biosimilar; UCB sells its generic business; one-third of children with ADHD are diagnosed before they turn six

Five things for pharma marketers to know: Monday, May 18

Five things for pharma marketers to know: Monday, May 18

By

Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition